ASP Isotopes (NASDAQ:ASPI – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.11), Zacks reports. The company had revenue of $5.12 million during the quarter, compared to analysts’ expectations of $4.47 million. ASP Isotopes had a negative net margin of 644.40% and a negative return on equity of 112.46%.
ASP Isotopes Trading Down 0.2%
Shares of ASPI opened at $4.27 on Friday. ASP Isotopes has a fifty-two week low of $3.51 and a fifty-two week high of $14.49. The stock has a fifty day moving average of $5.18 and a two-hundred day moving average of $5.43. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.37 and a current ratio of 4.39. The company has a market capitalization of $654.63 million, a PE ratio of -3.23 and a beta of 3.61.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $13.00.
Insiders Place Their Bets
In related news, Director Michael Gorley sold 30,000 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $6.27, for a total value of $188,100.00. Following the completion of the transaction, the director directly owned 87,908 shares in the company, valued at approximately $551,183.16. This represents a 25.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Paul Elliot Mann sold 83,759 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $7.76, for a total value of $649,969.84. Following the transaction, the chief executive officer owned 9,579,845 shares in the company, valued at $74,339,597.20. This trade represents a 0.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 279,079 shares of company stock valued at $2,049,208. 14.40% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On ASP Isotopes
A number of institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in ASP Isotopes by 9.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,613 shares of the company’s stock worth $148,000 after purchasing an additional 2,709 shares during the last quarter. Rhumbline Advisers grew its stake in shares of ASP Isotopes by 20.9% during the 2nd quarter. Rhumbline Advisers now owns 78,994 shares of the company’s stock valued at $581,000 after buying an additional 13,668 shares during the period. XTX Topco Ltd purchased a new position in shares of ASP Isotopes in the 2nd quarter worth about $178,000. New York State Common Retirement Fund lifted its holdings in shares of ASP Isotopes by 418.2% during the 2nd quarter. New York State Common Retirement Fund now owns 17,100 shares of the company’s stock valued at $126,000 after acquiring an additional 13,800 shares in the last quarter. Finally, Invesco Ltd. raised its position in ASP Isotopes by 2,205.0% in the second quarter. Invesco Ltd. now owns 471,219 shares of the company’s stock valued at $3,468,000 after purchasing an additional 450,776 shares during the period. 16.80% of the stock is currently owned by hedge funds and other institutional investors.
About ASP Isotopes
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
Read More
- Five stocks we like better than ASP Isotopes
- Microsoft’s Maia 300 Chip Targets NVIDIA’s AI Dominance
- 3 Unexpected ETFs Crushing the Market This Summer
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
Receive News & Ratings for ASP Isotopes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASP Isotopes and related companies with MarketBeat.com's FREE daily email newsletter.
